Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bispecific Antibody Therapy in Lupus Nephritis
NCT06975787Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1 trial of vonsetamig and odronextamab in lupus nephritis (LN), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities up to 56 days and Treatment Emergent Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
vonsetamigodronextamab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06975787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975787.